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Supplementary Information 
Supplementary Figure 1. Ethnicity and gene expression in MyBrCa breast tumours. Principal 
component analysis of gene expression in MyBrCa tumours showing the overlap between 
different ethnicities (n: Chinese=498, Indian=19, Malay=26, Other=9). 
Supplementary Figure 2. Molecular subtypes of Malaysian breast cancer. Comparison of 
PAM50 molecular subtype distribution across Malaysian (MyBrCa), other Asian (Korean1, TCGA2 
Asian), and Caucasian (TCGA2 Caucasian, METABRIC3, Nik-Zainal 20164) cohorts. Comparisons 
were done using the full cohorts (a) as well as with only patients below (b) or above (c) the age 
of 50 as a rough proxy for menopausal status. Numbers above the bars are p-values denoting 
significant differences between Asians and Caucasians for that subtype, as determined by 





























































Supplementary Figure 3. Unsupervised clustering of MyBrCa and TCGA Caucasian samples. K-means 
consensus clustering of MyBrCa and TCGA Caucasian gene expression data in order to determine the 
existence of exclusive Asian or Caucasian subtypes. (a) Plot of the relative change in area under the 
empirical cumulative distribution (CDF) of a consensus matrix, used to determine that the maximum 
number of meaningful clusters in our data is k=11. (b) Frequency of samples in each k-means cluster by 
cohort when k=11. P-values are for Pearson’s chi-square test. P-values above 0.1 are not shown. (c) 











Supplementary Figure 4. Classification of MyBrCa TNBC 
samples. (a) Heatmap of MyBrCa TNBC samples (n=94) 
showing the classification of samples into mesenchymal (MES), 
immuno-modulatory (IM), basal-like immuno-suppressed (BLIS) 
and luminal androgen receptor (LAR) subtypes, using the 80-
gene signature from Burstein et al. (2015)5 on gene median-
centered transcript per million (TPM) expression scores. (b) Pie 
chart showing the proportion of MyBrCa TNBC samples that 
were classified into each subtype. 
a 
b 
Supplementary Figure 5. Somatic mutation positions of TP53, PIK3CA and GATA3 in 
MyBrCa. Lollipop plots depicting positions of truncating, missense and inframe somatic 
mutations, as well as the most prominent positions in each gene. 
Supplementary Figure 6. Mutational prevalence of main breast cancer genes in Asian and 
Caucasian breast tumours, separated by ER status. Comparison of mutational prevalence of 
main breast cancer genes in Asian (MyBrCa, Korean, TCGA Asian, WGS Asian) and Caucasian 
(METABRIC, TCGA Caucasian, WGS Caucasian) breast tumours, in all samples (top), or 
separated according to their ER status (middle and bottom). P-values from 2-sided Student’s 
t-test comparing Asian versus Caucasian samples. 
Supplementary Figure 7. Mutational prevalence of main breast cancer genes in Asian and 
Caucasian breast tumours, separated by IntClust. Comparison of mutational prevalence of main 
breast cancer genes in Asian and Caucasian, limited to all samples from Integrative Clusters 3,5, 
8 and 10 – these IntClusts are with the most samples overall to permit meaningful cross 
comparison. P-value from 2-sided Student’s t-test comparing Asian versus Caucasian samples. 
Supplementary Figure 8. Mutational prevalence of main breast cancer genes in Asian and 
Caucasian breast tumours, separated by PAM50. Comparison of mutational prevalence of main 
breast cancer genes in Asian and Caucasian, limited to all samples with available PAM50 
classification (a) and to PAM50 subtypes (b). P-values from 2-sided Student’s t-test comparing 
Asian versus Caucasian samples. 
a 
b 
Supplementary Figure 9. Comparison of TP53 somatic mutations in Asians and Caucasians. 
Positions of TP53 mutations in ER+ and ER– samples, separated by ethnicity. Right: Percent of 
mutations in each category that are located in transactivating, DNA-binding, or tetramisation 































Supplementary Figure 10. Prevalence of CDH1 somatic mutations in different histological 
subtypes. Comparison of prevalence of somatic mutations in the CDH1 gene in the MyBrCa and 
TCGA Caucasian cohorts, stratified by histological subtypes (IDC: Invasive ductal carcinoma; ILC: 
Invasive lobular carcinoma). The absolute values for IDC are MyBrCa: 11/515 (2.1%) versus TCGA 
Cau.: 4/424 (0.9%), while the absolute values for ILC are MyBrCa: 7/18 (39%) vs TCGA Cau.: 
67/150 (44.7%). P-values shown are determined by chi-square test. 
Supplementary Figure 11. Driver genes in Asian and Caucasian breast tumours. Bar plots depict 
mutation rates of driver genes (top panels), as well as ONC (middle) and TSG (bottom) scores in 




Supplementary Figure 12. Association patterns of driver genes in Asian and Caucasian breast 
tumours. Heat maps depicting co-occurrence (green) or mutual exclusivity (purple) of somatic 
SNV or indel mutations in all Asian (left) and Caucasian (right) breast tumours. 
Supplementary Figure 13. Copy number profile of MyBrCa tumours from shallow WGS. 
Frequency of copy-number amplifications, gain, loss, and deletions are based on 100kb-window 
segmented calls, as called by QDNASeq. 
Supplementary Figure 14. Copy number aberration (CNA) of MyBrCa samples. Copy number 
aberration plots depicting the frequencies of CNAs in each IntClust. 
Supplementary Figure 15.  Cancer cell fraction of nine 
driver genes across Integrative Cluster subtypes in 
Malaysian breast tumours. Comparison of cancer cell 
fraction (CCF) – the proportion of cancer cells carrying a 
mutation for a specific gene – for nine common breast 
cancer driver genes across Integrative Cluster subtypes 
in the MyBrCa cohort. The interquartile range of CCF 
across all samples for each gene is shown in grey. Only 
subtypes with at least three samples in that category 
are shown. 2. The boxes in box plots indicate 25th 
percentile, median, and 75th percentile, while whiskers 
show the maximum and minimum values within 1.5 
times the inter-quartile range from the edge of the box. 
Supplementary Figure 16. Mutational signatures of Asian and Caucasian breast tumours. 
Mutational spectra of Asian tumours (MyBrCa, Korean, TCGA Asian, WGS Asian) and Caucasian 
(TCGA Caucasian, WGS Caucasian) generated from all samples from each dataset. Also shown 
are the relative contributions of the mutational signatures in each data set (bottom bars). 
Supplementary Figure 17. Mutational signatures of Asian and Caucasian breast tumours. 
Prevalence of mutational signatures in Asian (MyBrCa and Korea) and Caucasian (TCGA Caucasian) 
tumours, limited to IntClusts 3, 5, 8 and 10. 
B 
Signatures 
Supplementary Figure 18. Mutational signatures of Asian and Caucasian breast tumours. 
Prevalence of mutational signatures in Asian (MyBrCa and Korea) and Caucasian (TCGA 
Caucasian) breast tumours, limited PAM50 subtypes. 
Signatures 
Supplementary Figure 19. Comparison of immune scores across Integrative Cluster subtypes 
between MyBrCa samples and Caucasian samples from TCGA. P-values are for two-sided t-tests 
between MyBrCa and Caucasian samples for that specific cluster. 
Supplementary Figure 20. Comparison of IMPRES scores across PAM50 subtypes in the MyBrCa, 
Korean, METABRIC, and TCGA cohorts. Asterisks indicate significant differences between MyBrCa 
and TCGA samples from a 2-sided t-test (p<0.001). Exact p-values, from left to right, are p<2.2e-16 
(Luminal A), p<2.2e-16 (Luminal B), p=7.6e-11 (Her2), and p=9.5e-8 (Basal). Outliers not shown. 
Supplementary Figure 21. CIBERSORT analysis of MyBrCa, Korean, and TCGA BRCA samples. 
Highlighted boxes indicate immune cell types that were significantly enriched in either TCGA or 
MyBrCa relative to the other using a 2-sided t-test (p<0.05), with the exact p-values shown. 
Outliers not shown. The boxes in box plots indicate 25th percentile, median, and 75th percentile, 
while whiskers show the maximum and minimum values within 1.5 times the inter-quartile range 
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Supplementary Figure 22. TIMER analysis of MyBrCa, Korean, and TCGA BRCA samples. 
Highlighted boxes indicate immune cell types that were significantly enriched in either TCGA or 
MyBrCa relative to the other using a 2-sided t-test (p<0.05), with the exact p-values shown. 
Outliers not shown. 
p=0.033 p=0.002 







Supplementary Figure 23. GSVA analysis of MyBrCa, and TCGA BRCA samples using gene sets for 
individual immune cell types from Bindea et al (2013)6. Highlighted boxes indicate immune cell 
types that were significantly enriched in either TCGA or MyBrCa relative to the other using a 2-








p<2.2e-16 p<2.2e-16 p<2.2e-16 
p<2.2e-16 p<2.2e-16 p<2.2e-16 p<2.2e-16 p<2.2e-16 
p<2.2e-16 
Supplementary Figure 24. Comparison of ESTIMATE (left) and IMPRES (right) immune scores 
versus CD3 (top) and CD8 (bottom) IHC staining in the MyBrCa cohort (n=124).  Trendlines 
































































































CD8 Staining (%) 
rs = 0.55 
p=1.3e-6 
rs = 0.52 
p=6.7e-6 
rs = 0.50 
p=1.9e-5 
rs = 0.51 
p=8.3e-6 
Supplementary Figure 25. Comparison of tumour heterogeneity between the MyBrCa and TCGA 
cohorts across Integrative Cluster subtypes. Tumour heterogeneity is quantified here using Mutant 
Allele Tumour Heterogeneity (MATH) scores. P-values shown are for 2-sided student’s t-tests. Exact 
p-values for IC4- and IC10 are p=2.3e-5 and p=5.6e-6, respectively. 






















KEGG SLE GSVA 
Supplementary Figure 26. Association of IMPRES scores with GSVA Scores for the KEGG 
Systemic Lupus Erythematosus pathway, KEGG Cytosolic DNA-sensing pathway, and KEGG TGF-
Beta Signaling Pathway. Figures shown are for the MyBrCa cohort samples only. 
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Supplementary Figure 27. Cox Proportional Hazard model of overall survival for MyBrCa 
patients. Names of the included variables are bolded on the left, p-values of the 2-tailed Z-test for 
each individual variable are indicated on the right. Only patients with more than 2 years of follow 
up data were included (n=367). Error bars indicate 95% confidence intervals of the hazard ratio. 
Supplementary Table 1. Cohort characteristics. Statistical significance determined with a 
chi-square test, excluding N/As. 
  MyBrCa TCGA Statistical significance 
Subjects (n) 560 1,097 
Patient age (yr) 53.4 ± 11.7 58.4 ± 13.2 p<1e-4 
Parity (n) 3.2 ± 1.6 NA 
Menopausal status (n(%)) p<1e-5 
Pre-menopausal 173 (30.9) 229 (20.9) p<1e-5 
Post-menopausal 243 (43.4) 705 (64.3) p<1e-5 
Peri-menopausal - 39 (3.6) 
N/A  144 (25.7) 124 (11.3) 
Clinical subtype (n(%)) p<1e-5 
ER+/HER2- 274 (48.9) 597 (54.4) p<1e-5 
ER+/HER2+ 75 (13.4) 142(12.9) p=0.51 
ER-/HER2+ 85 (15.2) 42 (3.8) p<1e-5 
TNBC 116 (20.7) 174 (15.9) p=0.17 
N/A 10 (1.8) 142 (12.9) 
TNM stage (n(%)) p=3.3e-4 
0 19 (3.4) - 
I 96 (17.1) 183 (16.7) p=0.68 
II 256 (45.7) 621 (56.6) p=1.1e-4 
III 168 (30.0) 249 (22.7) p=4.9e-4 
IV 17 (3.0) 20 (1.8) p=0.10 
N/A 4 (0.7) 24 (2.2) 
Histology subtype (n(%)) p<1e-5 
Lobular Carcinoma 18 (3.2) 203 (18.5) p<1e-5 
Ductal Carcinoma  520 (92.9) 784 (71.5) p<1e-5 
Other 19 (3.4) 109 (9.9) p<1e-5 
N/A 3 (0.5) 1 (0.1) 
Race (n(%)) 
Asian 543 (97) 61 (5.6) p<1e-5 
 - Malaysian (Chinese) 498 (89) - 
 - Malaysian (Malay) 26 (4.6) - 
 - Malaysian (Indian) 19 (3.4) - 
Black - 183 (16.7) 
White (Hispanic) - 34 (3.1) 
White (Non-Hispanic) - 656 (59.8) 
Other 9 (1.6) 72 (6.6) 
N/A 8 (1.4) 91 (8.3) 
Supplementary Table 2. Driver gene analysis on Asian and Caucasian ER+ tumours. Percentage of 
samples carrying the mutated driver genes, as well as ONC and TSG scores (see Methods) for 
Asian and Caucasian ER+ tumours. Rows in orange are genes that have been identified as cancer 
drivers by Integrative Onco Genomics7 (see Methods). 
%Asian %Caucasian ONC(Asian) ONC(Caucasian) TSG(Asian) TSG(Caucasian)
AKT1 4.3 1.7 87.0 69.2 0.0 7.7
ANKRD11 0.7 1.7 25.0 6.3 0.0 37.5
ANKRD12 0.9 1.8 20.0 6.7 20.0 33.3
ARHGAP35 0.7 1.5 25.0 8.3 50.0 41.7
ARID1A 4.3 3.5 4.2 3.4 79.2 62.1
ATP2B2 1.3 1.4 14.3 7.7 0.0 7.7
ATR 2.6 2.2 6.7 5.0 6.7 25.0
BRCA1 0.9 1.0 20.0 12.5 20.0 0.0
BRCA2 1.9 2.2 10.0 5.3 40.0 26.3
C1orf173 0.7 1.3 25.0 7.7 0.0 38.5
CASZ1 0.4 2.4 0.0 10.5 50.0 26.3
CBFB 4.8 4.0 3.8 6.5 80.8 74.2
CDH1 5.6 9.2 3.3 2.6 80.0 76.6
CDH24 0.4 1.0 50.0 12.5 0.0 62.5
CDKN1B 0.9 1.0 0.0 9.1 80.0 54.5
CHD4 1.9 2.7 10.0 9.1 10.0 22.7
CHD6 0.9 2.7 20.0 4.5 0.0 27.3
CREBBP 1.9 1.7 10.0 7.1 0.0 14.3
CSMD1 4.1 5.0 4.0 8.7 24.0 4.3
CTCF 2.0 2.8 9.1 18.2 36.4 31.8
DAZAP1 0.6 1.0 0.0 10.0 33.3 50.0
DYSF 2.2 3.5 7.7 2.9 7.7 20.6
ERBB2 1.7 2.6 11.1 30.4 0.0 0.0
FBN3 1.5 2.8 12.5 4.2 0.0 20.8
FER1L6 1.7 1.3 11.1 8.3 0.0 8.3
FLT4 0.6 1.3 33.3 8.3 0.0 8.3
FOXA1 0.9 3.1 20.0 30.0 20.0 10.0
FSIP2 1.7 2.8 11.1 4.3 11.1 21.7
GATA3 15.6 14.2 1.1 3.6 93.3 85.7
GIGYF2 0.9 1.2 20.0 11.1 0.0 55.6
GPR98 3.4 3.9 4.5 2.9 4.5 17.6
GPS2 0.4 1.4 0.0 0.0 50.0 72.7
HECTD4 0.4 2.3 50.0 4.0 0.0 36.0
HELZ 0.7 1.8 20.0 5.3 20.0 31.6
HSPG2 1.7 2.3 11.1 4.3 22.2 26.1
JAG1 1.1 1.9 16.7 6.7 16.7 33.3
JAK1 0.2 1.2 0.0 9.1 0.0 72.7
JMJD1C 1.1 2.2 16.7 5.0 16.7 35.0
KDM6A 0.7 2.3 25.0 5.6 0.0 38.9
KIAA0947 0.6 1.3 33.3 7.1 66.7 35.7
KMT2A 1.5 3.0 11.1 4.0 44.4 32.0
KMT2B 1.3 1.8 14.3 5.6 14.3 38.9
KMT2C 4.7 8.5 3.6 1.3 75.0 60.3
LRP1 1.5 3.3 12.5 3.4 12.5 31.0
MAP2K4 2.4 4.9 15.4 10.5 30.8 52.6
MAP3K1 8.4 9.9 5.6 3.8 53.7 77.4
MAP3K4 1.1 2.2 16.7 5.9 0.0 35.3
MED23 3.4 1.4 5.6 8.3 27.8 58.3
MLLT4 1.7 2.2 11.1 5.3 44.4 36.8
MYB 0.6 1.9 33.3 5.9 66.7 47.1
NACAD 0.4 1.5 50.0 7.1 0.0 35.7
NAV3 0.7 2.1 20.0 5.6 20.0 38.9
NCOR1 2.0 5.5 9.1 4.4 63.6 44.4
NF1 4.1 3.2 4.5 3.8 31.8 30.8
NIPBL 1.9 1.8 10.0 5.6 20.0 22.2
NOTCH2 0.9 3.0 16.7 3.8 0.0 26.9
PIK3CA 32.0 35.4 71.6 66.7 1.1 1.9
PTEN 4.3 4.5 4.0 2.9 68.0 62.9
RB1 1.5 2.2 12.5 5.6 50.0 44.4
RUNX1 2.6 3.2 6.7 4.0 46.7 64.0
SACS 0.7 2.1 25.0 4.5 0.0 27.3
SBF1 0.4 1.5 0.0 6.7 0.0 33.3
SETD2 1.7 1.5 11.1 6.7 22.2 40.0
SF3B1 1.5 3.5 12.5 58.6 0.0 0.0
SMCHD1 0.6 1.8 25.0 6.3 0.0 31.3
SPEN 1.5 4.2 11.1 2.0 55.6 46.9
TAF1B 0.2 0.4 0.0 33.3 100.0 33.3
TBX3 3.0 4.2 11.8 5.6 52.9 55.6
TMEM247 0.2 1.0 0.0 18.2 0.0 45.5
TP53 30.7 17.6 12.0 15.0 38.6 32.1
TRIP12 1.5 1.4 11.1 7.1 33.3 35.7
USP9X 1.5 2.3 12.5 5.3 0.0 26.3
VPS13C 3.4 2.4 5.3 4.5 0.0 22.7
WDR52 0.4 1.0 0.0 11.1 0.0 55.6
ZFHX3 1.7 1.9 10.0 5.9 10.0 41.2
ZFP36L1 1.1 1.0 16.7 0.0 83.3 37.5
ZFPM1 1.3 1.3 14.3 9.1 85.7 81.8
ZMYM3 0.7 1.5 20.0 6.7 20.0 33.3
ZNF142 1.1 1.4 16.7 8.3 0.0 41.7
ZNF292 0.7 1.8 25.0 4.8 25.0 23.8
ER+
gene
Supplementary Table 3. Driver gene analysis on Asian and Caucasian ER– tumours. Percentage of 
samples carrying the mutated driver genes, as well as ONC and TSG scores (see Methods) for 
Asian and Caucasian ER– tumours. Rows in orange are genes that have been identified as cancer 
drivers by Integrative Onco Genomics7 (see Methods). 
%Asian %Caucasian ONC(Asian) ONC(Caucasian) TSG(Asian) TSG(Caucasian)
AKT1 1.2 1.1 50.0 66.7 0.0 0.0
ANKRD11 2.4 2.7 12.5 11.1 0.0 0.0
ANKRD12 1.2 1.1 25.0 0.0 0.0 33.3
ARHGAP35 1.5 2.7 0.0 12.5 16.7 50.0
ARID1A 1.8 1.5 16.7 25.0 16.7 50.0
ATP2B2 3.0 3.1 9.1 16.7 0.0 41.7
ATR 4.2 5.0 5.6 7.7 5.6 0.0
BRCA1 3.6 3.1 7.1 11.1 42.9 55.6
BRCA2 2.7 2.7 11.1 12.5 22.2 62.5
C1orf173 2.1 2.7 14.3 14.3 14.3 14.3
CASZ1 1.2 1.1 0.0 33.3 50.0 0.0
CBFB 0.3 1.1 0.0 33.3 0.0 33.3
CDH1 0.6 1.9 0.0 20.0 0.0 20.0
CDH24 0.0 0.4 0.0 100.0 0.0 0.0
CDKN1B 0.0 0.8 0.0 33.3 0.0 33.3
CHD4 2.4 2.3 10.0 16.7 0.0 16.7
CHD6 2.1 4.6 14.3 8.3 0.0 16.7
CREBBP 3.6 4.6 7.1 7.7 35.7 23.1
CSMD1 5.6 8.4 3.7 4.3 7.4 13.0
CTCF 1.5 0.8 20.0 0.0 40.0 50.0
DAZAP1 0.3 1.5 0.0 25.0 0.0 25.0
DYSF 2.1 5.4 11.1 6.3 11.1 18.8
ERBB2 3.3 1.9 14.3 20.0 0.0 0.0
FBN3 2.1 4.2 14.3 9.1 0.0 27.3
FER1L6 3.3 4.6 8.3 8.3 8.3 41.7
FLT4 1.5 2.7 20.0 10.0 0.0 50.0
FOXA1 0.3 1.9 0.0 14.3 0.0 14.3
FSIP2 5.6 4.6 5.0 6.7 10.0 6.7
GATA3 1.5 0.4 0.0 0.0 80.0 100.0
GIGYF2 2.1 3.4 11.1 11.1 11.1 11.1
GPR98 6.2 4.6 4.5 7.1 4.5 35.7
GPS2 0.3 0.8 100.0 0.0 0.0 50.0
HECTD4 3.0 3.8 10.0 8.3 0.0 16.7
HELZ 2.4 1.9 10.0 16.7 10.0 0.0
HSPG2 3.6 7.3 7.1 5.3 7.1 5.3
JAG1 2.7 1.5 11.1 25.0 11.1 0.0
JAK1 1.2 0.8 16.7 0.0 33.3 50.0
JMJD1C 2.1 2.3 12.5 14.3 0.0 0.0
KDM6A 0.9 2.7 25.0 12.5 25.0 25.0
KIAA0947 1.5 2.7 16.7 12.5 33.3 12.5
KMT2A 2.7 1.1 11.1 33.3 11.1 0.0
KMT2B 1.2 1.1 25.0 33.3 0.0 33.3
KMT2C 5.9 8.0 7.7 3.8 30.8 38.5
LRP1 3.0 7.3 10.0 4.8 0.0 9.5
MAP2K4 0.3 1.1 0.0 0.0 0.0 66.7
MAP3K1 0.9 2.7 0.0 14.3 0.0 42.9
MAP3K4 2.1 0.4 11.1 0.0 11.1 0.0
MED23 1.2 1.1 25.0 33.3 25.0 33.3
MLLT4 2.1 3.4 14.3 10.0 28.6 20.0
MYB 1.2 0.8 16.7 50.0 0.0 0.0
NACAD 0.6 0.8 50.0 50.0 0.0 0.0
NAV3 2.7 4.6 9.1 8.3 9.1 0.0
NCOR1 3.6 3.8 7.1 10.0 42.9 0.0
NF1 5.3 5.4 4.5 6.7 36.4 53.3
NIPBL 3.9 5.0 5.9 7.1 23.5 35.7
NOTCH2 2.7 4.6 11.1 5.6 33.3 27.8
PIK3CA 21.1 11.9 59.8 47.4 2.4 5.3
PTEN 4.5 4.2 5.9 7.7 76.5 69.2
RB1 4.7 9.6 5.9 3.7 64.7 55.6
RUNX1 2.1 1.1 14.3 0.0 42.9 0.0
SACS 2.7 4.6 10.0 7.1 0.0 7.1
SBF1 0.6 0.8 50.0 50.0 0.0 50.0
SETD2 3.0 1.9 10.0 16.7 20.0 16.7
SF3B1 0.6 0.4 50.0 0.0 0.0 0.0
SMCHD1 0.9 3.1 25.0 11.1 0.0 0.0
SPEN 3.3 3.4 7.1 11.1 21.4 22.2
TAF1B 1.5 2.7 20.0 12.5 60.0 62.5
TBX3 1.5 1.1 20.0 25.0 60.0 0.0
TMEM247 0.0 0.4 0.0 50.0 0.0 0.0
TP53 67.4 71.3 22.2 12.0 34.8 46.4
TRIP12 1.2 3.4 14.3 11.1 0.0 22.2
USP9X 2.7 4.2 9.1 9.1 9.1 36.4
VPS13C 3.0 4.2 6.7 7.7 13.3 0.0
WDR52 2.7 5.0 7.7 7.7 7.7 0.0
ZFHX3 2.4 2.3 10.0 12.5 50.0 25.0
ZFP36L1 0.9 1.1 33.3 0.0 33.3 33.3
ZFPM1 0.3 0.4 0.0 0.0 0.0 0.0
ZMYM3 1.8 1.5 16.7 0.0 16.7 75.0
ZNF142 0.3 1.1 0.0 33.3 100.0 0.0





























21 2.0 0.66 
BRCA2 10 1.8 20 1.9 0.96 
PALB2 6 1.1 3 0.3 0.036 
ATM 2 0.4 9 0.8 0.27 
CHEK2 1 0.2 3 0.3 0.71 
Supplementary Table 4. Germline mutations in MyBrCa and TCGA breast tumours. Table 
compares the frequency of germline mutations in highly-penetrant risk genes in the MyBrCa and 
TCGA cohorts. Significance determined by chi-square tests. 
Rank Hallmark Pathway |NES| p-val FDR Higher in 
1 Mitotic Spindle 2.061 0 0.012 TCGA 
2 Estrogen Response Early 2.016 0 0.009 TCGA 
3 UV Response Down 1.953 0 0.018 TCGA 
4 Allograft Rejection 1.928 0.004 0.088 MyBrCa 
5 TGF Beta Signaling 1.818 0.011 0.041 TCGA 
6 Notch Signaling 1.762 0.007 0.051 TCGA 
7 Apical Surface 1.753 0.004 0.047 TCGA 
8 Wnt Beta Catenin Signaling 1.716 0.012 0.051 TCGA 
9 Complement 1.709 0.019 0.289 MyBrCa 
10 Oxidative Phosphorylation 1.578 0.092 0.418 MyBrCa 
11 Inflammatory Response 1.565 0.100 0.339 MyBrCa 
12 Interferon Gamma Response 1.551 0.113 0.292 MyBrCa 
13 Interferon Alpha Response 1.542 0.117 0.253 MyBrCa 
14 Hedgehog Signaling 1.526 0.047 0.139 TCGA 
15 Adipogenesis 1.525 0.061 0.239 MyBrCa 
Supplementary Table 5. Pathway analysis of MyBrCa versus TCGA tumours. Top 15 most 
differentially enriched pathways between the MyBrCa and TCGA cohorts as indicated by Gene Set 
Enrichment Analysis of MSigDB hallmark pathways, ranked by absolute normalized enrichment 
score (|NES|). Immune system-related gene sets are highlighted in blue. 
Supplementary Table 6. Regression analysis of IMPRES score in the MyBrCa and TCGA cohorts 
(n=1657) using a multiple linear model to control for clinical variables that differ between 
cohorts. Asterisks indicate the level of significance of two-sided t-tests (Pr(>|t|)) for each 
variable (*< 0.05; **<0.01; ***<0.001).  
  Variable Est. Coefficient Std. Error t-value Pr(>|t|) Sig. 
Age Age -0.001 0.004 -0.306 0.760   
Stage Stage 0 -0.964 0.577 -1.671 0.095 . 
(Relative to Stage 1) Stage 2 -0.006 0.120 -0.048 0.962 
Stage 3 -0.025 0.138 -0.181 0.856 
Stage 4 0.093 0.388 0.240 0.810 
Histological subtype ILC 0.154 0.132 1.162 0.246   
(Relative to IDC) Other  -0.214 0.170 -1.261 0.208   
  DCIS 1.210 0.860 1.407 0.160   
Menopausal status Post-menopausal -0.070 0.114 -0.611 0.541 
(Relative to Pre-menopausal) Peri-menopausal -0.758 0.270 -2.811 0.005 ** 




-0.520 0.162 -3.209 0.001 
** 
IHC HR+ -1.022 0.106 -9.624 <2e-16 *** 
HER2+ -0.167 0.110 -1.521 0.129 
Ethnicity Caucasian -1.013 0.142 -7.143 0.000 *** 
(Relative to Asian) Other  -0.742 0.172 -4.326 0.000 *** 
Adjusted R-squared: 0.233 
Model p-value: <2e-16 
  Variable Est. Coefficient Std. Error t-value Pr(>|t|) Sig. 
Integrative Cluster Subtype IntClust 1 -0.131 0.341 -0.383 0.702   
(Relative to IntClust 3) IntClust 2 0.281 0.464 0.606 0.545   
IntClust 4+ 0.329 0.319 1.032 0.303   
  IntClust 4- 1.013 0.348 2.916 0.004 ** 
  IntClust 5 0.335 0.304 1.101 0.272   
  IntClust 6 0.091 0.421 0.215 0.830   
  IntClust 7 0.658 0.310 2.126 0.034 * 
  IntClust 8 0.012 0.291 0.04 0.968   
  IntClust 9 0.644 0.318 2.029 0.043 * 
  IntClust 10 1.007 0.312 3.227 0.001 ** 
Histological subtype Histology - IDC -0.198 0.587 -0.338 0.735 
(Relative to DCIS) Histology - ILC -0.701 0.768 -0.913 0.362 
Histology - Other -0.560 0.978 -0.572 0.567 
Clinical metrics Grade 0.185 0.149 1.242 0.215   
  Stage (AJCC6) 0.108 0.105 1.028 0.305   
  Size -0.019 0.051 -0.383 0.702   
  Tumor Content 0.000 0.004 -0.005 0.996   
  Neoadjuvant treatment -0.309 0.413 -0.748 0.455   
Physical metrics Age -0.015 0.008 -2.012 0.045 * 
Weight -0.052 0.098 -0.533 0.594 
Height 3.350 7.421 0.451 0.652 
BMI 0.118 0.243 0.485 0.628 
Demographic factors Ethnicity – Indian1 -0.214 0.441 -0.486 0.628   
1Relative to Chinese Ethnicity - Malay1 -0.238 0.382 -0.621 0.535   
2Relative to Income <5,000 Ethnicity - Other1 -0.250 0.530 -0.472 0.637   
  Age of menarche 0.057 0.055 1.041 0.299   
  Family history of cancer 0.173 0.181 0.953 0.341   
  Income >10,0002 0.108 0.230 0.471 0.638   
  Income 5-10,0002 0.042 0.180 0.231 0.817   
  Education -0.167 0.130 -1.289 0.198   
  Regular alcohol drinker 0.064 0.202 0.316 0.752   
Adjusted R-squared: 0.0674 
Model p-value: 0.0047 
Supplementary Table 7. Regression analysis of IMPRES score in the MyBrCa cohort (n=340) 
using a multiple linear model across available clinical and demographic data. Asterisks indicate 
the level of significance of two-sided t-tests (Pr(>|t|)) for each variable (*< 0.05; **<0.01; 
***<0.001).  







Significant variables from IntClust 1a 0.096 0.295 0.324 0.746   
clinical-demographic IntClust 2a 0.521 0.379 1.374 0.170   
linear model IntClust 4+a 0.472 0.292 1.617 0.107   
aRelative to IntClust 3 IntClust 4-a 0.826 0.289 2.859 0.004 ** 
IntClust 5a 0.622 0.266 2.341 0.020 * 
  IntClust 6a 0.258 0.350 0.737 0.462   
  IntClust 7a 0.768 0.268 2.868 0.004 ** 
  IntClust 8a 0.180 0.254 0.710 0.478   
  IntClust 9a 0.948 0.287 3.305 0.001 ** 
  IntClust 10a 1.197 0.290 4.121 0.000 *** 
  Age 0.002 0.006 0.363 0.717   
Germline mutations Germline mutation in HR pathway -0.055 0.236 -0.232 0.817 
1Relative to A3B deletion - 
Homozygous 
A3B deletion - Heterozygous1 -0.234 0.181 -1.295 0.196 
A3B deletion - Normal1 -0.345 0.189 -1.827 0.068 . 
Somatic mutations Tumor Mutation Burden 0.000 0.001 0.347 0.729   
  TP53 somatic mutations -0.037 0.144 -0.260 0.795   
Mutational signatures Signature 1 0.343 0.351 0.977 0.329 
Signature 2 0.553 0.636 0.868 0.386 
Signature 3 1.281 0.472 2.716 0.007 ** 
Signature 13 0.559 0.715 0.782 0.434 
Tumour heterogeneity Log PyClone Clusters -0.252 0.079 -3.179 0.002 ** 
  MATH -0.795 0.883 -0.901 0.368   
Neoantigens HLA A maximum binding affinity -0.005 0.002 -2.898 0.004 ** 
HLA A,B,C maximum binding 
affinity 
0.009 0.003 2.776 0.006 
** 
HLA A neoantigen count 0.000 0.008 -0.023 0.981 
HLA A,B,C neoantigen count 0.004 0.005 0.672 0.502 
Adjusted R-squared: 0.1324 
Model p-value: 2.214e-8 
Supplementary Table 8. Linear regression analysis of IMPRES score in the MyBrCa cohort 
(n=340) using available molecular data, adjusting for age and subtype. Asterisks indicate the 




























Supplementary Table 9. Pathway analysis of IMPRES high- versus low-scoring tumours. Pathway 
analysis comparing MyBrCa samples in the top quartile of IMPRES scores to samples in the bottom 
quartile reveals significant differences in the SLE pathway, cytosolic DNA-sensing pathway and 
TFG-Beta signaling pathway between the two groups. 
Supplementary Table 10. Comparison of Her2 positivity by different methods. Concordance 
between Her2 Positivity by IHC with ERBB2 copy number by sWGS, ERBB2 expression by RNASeq 







Del/Loss/Neutral Gain/Amp Low High No  Yes 
HER2- (IHC) 356 27 376 7 341 25 
HER2+ (IHC) 20 135 45 112 56 97 
            
Total 538 540 519 
Discordant 47 52 81 
Concordance rate (%) 91.3 90.4 84.4 
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